Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Baxdrostat on Ambulatory Blood Pressure in Chinese Participants With Uncontrolled Hypertension on Two or More Antihypertensive Medications Without Diuretics

NCT07686120 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07686120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Baxdrostat on Ambulatory Blood Pressure in Chinese Participants With Uncontrolled Hypertension on Two or More Antihypertensive Medications Without Diuretics
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
February 9, 2028
Enrollment
286 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

uncontrolled hypertension